Drug Profile
Glycopeptide - ProtoKinetix
Alternative Names: AAGP® moleculesLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Institut National des Sciences Appliquees de Rouen; ProtoKinetix
- Developer Imaginative Research Associates; ProtoKinetix; ProtoKinetix - Imaginative Research Associates (JV); University of British Columbia
- Class Anti-inflammatories; Eye disorder therapies; Glycopeptides; Glycoproteins; Skin disorder therapies; Small molecules
- Mechanism of Action Antioxidants; Free radical scavengers; Selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry eyes
- No development reported Inflammation; Macular degeneration; Ocular inflammation; Skin disorders
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Macular-degeneration in Canada (Implant)
- 28 Jan 2022 No recent reports of development identified for preclinical development in Ocular-inflammation in Canada (Topical)
- 15 Apr 2021 ProtoKinetix entered into an agreement with an undisclosed company to develop AAGP® for Dry eye disease and ocular inflammation (Topical)